Mesoblast provides topline results from phase 3 trial of rexlemestrocel-l for advanced chronic heart failure

New york, dec. 14, 2020 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from the landmark dream-hf phase 3 randomized controlled trial of its allogeneic cell therapy rexlemestrocel-l (revascor®) in 537 patients with advanced chronic heart failure1.
MESO Ratings Summary
MESO Quant Ranking